SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Deciphera Pharmaceuticals, Inc. (DCPH) , forward earnings yield 2.28%.
Criteria proven by this page:
- VALUE (50/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 43.8
- Analyst consensus target $26.32 (+2.9% upside) — modest upside expected.
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
50/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DCPH
Valuation Multiples
P/E (TTM)0.0
Forward P/E43.8
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio13.32
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.29
Forward EPS (Est.)$0.58
Book Value / Share$0.00
Revenue / Share$1.92
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield2.28%
Dividend Yield0.00%
Analyst Target$26.32 (+2.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.95 |
$0.00 |
$-19.82M |
- |
| 2016 |
$-1.24 |
$0.00 |
$-25.94M |
- |
| 2017 |
$-2.99 |
$0.00 |
$-50.28M |
- |
| 2018 |
$-2.82 |
$0.00 |
$-99.85M |
- |
| 2019 |
$-4.47 |
$25M |
$-191.49M |
-766% |
| 2020 |
$-4.78 |
$42.09M |
$-266.49M |
-633.2% |
| 2021 |
$-5.11 |
$96.15M |
$-296.84M |
-308.7% |
| 2022 |
$-2.37 |
$134.04M |
$-178.93M |
-133.5% |
| 2023 |
$-2.29 |
$163.36M |
$-194.94M |
-119.3% |
